A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley)
NCT02554812
ABOUT THIS STUDY
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
Pfizer Clinical Trials Contact Center
1-800-718-1021
- Histological or cytological diagnosis of advanced/metastatic solid tumor. Measurable disease by RECIST 1.1 with at least 1 measurable lesion that has not been previously irradiated. Availability of tumor specimen taken within 1 year prior to study entry, with no intervening systemic anti-cancer therapy. No prior PD-1/PDL-1 therapy allowed. Combination A: Phase 1b, patients with NSCLC that have progressed on standard therapy or for which no standard therapy is available, and Phase 2, patients with NSCLC, melanoma, SCCHN, TNBC in any line of therapy, SCLC, 1st line NSCLC. 1st line NSCLC must demonstrate to express PD-L1. Activating EGFR mutation, ALK, ROS1 translocation/rearrangements are not permitted. Combination B: Phase 1b, patients with advanced solid tumors (NSCLC, SCCHN, melanoma) that have progressed on standard therapy or for which no standard therapy is available, and Phase 2, patients with NSCLC, melanoma, or SCCHN. Up to 2 lines of prior therapy in advanced/metastatic disease setting allowed. Activating EGFR mutation, ALK, ROS1 translocation/rearrangements are not permitted. Combination C: Ovarian cancer, SCCHN, NSCLC, gastric cancer, platinum resistant ovarian cancer. Up to 2 lines of prior therapy in advanced/metastatic disease setting allowed. TGCT/PVNS that is either inoperable or requires extensive resection. Prior treatment with agents targeting CSF-1/CSF-1R not allowed. NSCLC activating EGFR mutation, ALK, ROS1 translocation/rearrangements are not permitted. Combination D: NSCLC, melanoma, SCCHN, bladder cancer. NSCLC activating EGFR mutation, ALK, ROS1 translocation/rearrangements are not permitted. Up to 2 lines of prior therapy in advanced/metastatic disease setting allowed. Combination F: Recurrent or metastatic SCCHN. One to three prior lines of systemic therapy for advanced stage or metastatic disease. Patients must have received anti PD-1/PD-L1 containing therapy (requires at least two doses of PD-1/PD-L1 agent).Disease progression no earlier than 6 weeks from initiation of the latest anticancer therapy. Evidence of radiologic progression is required. • Patient must be a candidate for intralesional administration with at least one tumor lesion which can be injected safely.
- ECOG performance status 0 or 1
- Estimated life expectancy of at least 3 months
- Adequate bone marrow, renal, and liver function
- Resolved acute effects of prior therapy
- Negative serum pregnancy test at screening
- Male and female patients able to have children must agree to use at least 1 highly effective method of contraception throughout the study and for at least 90 days after last dose
- Signed and dated informed consent
- Monoclonal antibody based anti-cancer therapy within 28 days prior to study entry or
small-molecule based anti-cancer therapy (targeted therapy or chemotherapy) within 14
days prior to study entry. Combination F:PD-1/PD-L1 agent within 14 days prior study
entry.
- Current or prior use of immunosuppressive medication within 7 days prior to study
entry
- Active autoimmune disease requiring systemic steroids or immunosuppressive agents
within 7 days prior to study entry
- Known prior or suspected hypersensitivity to investigational products
- Major surgery within 4 weeks or radiation therapy within 14 days prior to study entry
- Patients with known symptomatic brain metastases requiring steroids
- Previous high-dose chemotherapy requiring stem cell rescue
- Prior allogeneic stem cell transplant or organ graft
- Any of the following within 6 months prior to study entry: myocardial infarction,
uncontrolled angina, coronary/peripheral artery bypass graft, symptomatic congestive
heart failure, cerebrovascular accident, or transient ischemic attack
- Symptomatic pulmonary embolism within 6 months prior to study entry
- Known HIV or AIDS-related illness
- Active infection requiring systemic therapy
- Positive HBV or HCV test indicating acute or chronic infection
- Administration of a live vaccine within 4 weeks prior to study entry
- Diagnosis of other malignancy within 5 years, except for adequately treated basal cell
or squamous cell skin cancer, or carcinoma in situ of the breast or cervix, or
low-grade (Gleason ≤6) prostate cancer
- Participation in other studies involving investigational drug(s) within 4 weeks prior
to study entry and/or during study participation
- Persisting toxicity related to prior therapy >Grade 1
- Other severe acute or chronic medical condition
- Combo C :Existing periorbital edema.
- Combo C : Hypocalcemia, clinically significant bone disease or recent bone fracture
(within 12 weeks prior study entry)
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
- Houston, Texas
- Los Angeles, California
- Los Angeles, California
- Los Angeles, California
- Los Angeles, California
- Santa Monica, California
- Santa Monica, California
- Aurora, Colorado
- Aurora, Colorado
- Aurora, Colorado
- Aurora, Colorado
- Charleston, South Carolina
- Charleston, South Carolina
- Charleston, South Carolina
- Mount Pleasant, South Carolina
- North Charleston, South Carolina
- Toronto, Ontario
- Milano,
- Barcelona,
- Pittsburgh, Pennsylvania
- Pittsburgh, Pennsylvania
- Pittsburgh, Pennsylvania
- Warszawa,
- Encinitas, California
- La Jolla, California
- La Jolla, California
- La Jolla, California
- La Jolla, California
- Los Angeles, California
- Los Angeles, California
- Los Angeles, California
- Los Angeles, California
- San Diego, California
- Vista, California
- Washington, District of Columbia
- Aventura, Florida
- Miami Beach, Florida
- Sarasota, Florida
- Tampa, Florida
- Iowa City, Iowa
- Louisville, Kentucky
- Louisville, Kentucky
- Louisville, Kentucky
- Louisville, Kentucky
- Louisville, Kentucky
- Ann Arbor, Michigan
- Ann Arbor, Michigan
- Detroit, Michigan
- Detroit, Michigan
- Farmington Hills, Michigan
- Northville, Michigan
- New York, New York
- New York, New York
- New York, New York
- New York, New York
- New York, New York
- New York, New York
- New York, New York
- New York, New York
- Clinton, North Carolina
- Clinton, North Carolina
- Goldsboro, North Carolina
- Goldsboro, North Carolina
- Jacksonville, North Carolina
- Jacksonville, North Carolina
- Philadelphia, Pennsylvania
- Providence, Rhode Island
- Providence, Rhode Island
- Sioux Falls, South Dakota
- Sioux Falls, South Dakota
- Sioux Falls, South Dakota
- Sioux Falls, South Dakota
- Nashville, Tennessee
- Nashville, Tennessee
- Nashville, Tennessee
- Nashville, Tennessee
- Dallas, Texas
- Dallas, Texas
- Houston, Texas
- Seattle, Washington
- Seattle, Washington
- Camperdown, New South Wales
- Macquarie University, New South Wales
- Macquarie University, New South Wales
- North Sydney, New South Wales
- North Sydney, New South Wales
- Old Toongabie, New South Wales
- Brighton, Victoria
- Brighton, Victoria
- Heidelberg, Victoria
- Malvern, Victoria
- Malvern, Victoria
- Malvern, Victoria
- New South Wales,
- New South Wales,
- Edmonton, Alberta
- Vancouver, British Columbia
- Ottawa, Ontario
- Toronto, Ontario
- Montreal, Quebec
- Montreal, Quebec
- Villejuif, Cedex
- Villejuif,
- Kashiwa, Chiba
- Chuo-ku, Tokyo
- Warszawa, Mazowieckie
- Taipei,
- Taipei,
- London,
- London,
- London,
- London,
- London,
- Los Angeles, California
- Los Angeles, California
- Los Angeles, California
- Los Angeles, California
- Aurora, Colorado
- Aurora, Colorado
- Aurora, Colorado
- Aurora, Colorado
- Atlanta, Georgia
- Atlanta, Georgia
- Atlanta, Georgia
- Atlanta, Georgia
- Atlanta, Georgia
- Columbus, Ohio
- Columbus, Ohio
- Columbus, Ohio
- Columbus, Ohio
- Columbus, Ohio
- San Antonio, Texas
- San Antonio, Texas
Descriptive Information | |||||||
---|---|---|---|---|---|---|---|
Brief Title ICMJE | A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley) | ||||||
Official Title ICMJE | A PHASE 1B/2 OPEN-LABEL STUDY TO EVALUATE SAFETY, CLINICAL ACTIVITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF AVELUMAB (MSB0010718C) IN COMBINATION WITH OTHER CANCER IMMUNOTHERAPIES IN PATIENTS WITH ADVANCED MALIGNANCIES | ||||||
Brief Summary | This is a Phase 1b/2 dose-optimization study to evaluate safety, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of avelumab (MSB0010718C) in combination with other cancer immunotherapies in patients with locally advanced or metastatic solid tumors. The primary purpose is to assess the safety and early signs of efficacy of various avelumab combinations with other cancer immunotherapies, optimizing dosing regimens as appropriate, in a limited series of indications. | ||||||
Detailed Description | This is a Phase 1b/2, open-label, multi-center, multiple-dose, safety, clinical activity, PK, and PD study of avelumab in combination with other immune modulators in adult patients with locally advanced or metastatic solid tumors (eg, non-small cell lung cancer (NSCLC), melanoma, squamous cell carcinoma of the head and neck (SCCHN), triple-negative breast cancer (TNBC), gastric cancer, platinum resistant ovarian cancer, bladder cancer, small cell lung cancer (SCLC) and progressing tenosynovial giant cell tumor/pigmented villonodular synovitis (TGCT/PVNS) . In Phase 1b, this includes patients whose disease has progressed on standard of care therapy or for whom no standard therapy is available. In Phase 2, enrollment criteria regarding prior treatment(s) received varies by tumor type. Incorporation of the other immune modulators into this study is based on preclinical and clinical data supportive of single-agent tolerability and potential clinical benefit, as well as non-clinical data suggesting safety, tolerability and clinical benefit of the agent(s) in combination with avelumab. Combinations of avelumab plus other immune modulator(s) to be evaluated are as follows:
| ||||||
Study Type ICMJE | Interventional | ||||||
Study Phase ICMJE | Phase 2 | ||||||
Study Design ICMJE | Allocation: Randomized Masking: None (Open Label) Primary Purpose: Treatment | ||||||
Condition ICMJE | Advanced Cancer | ||||||
Intervention ICMJE |
| ||||||
Study Arms ICMJE |
| ||||||
Publications * | Not Provided | ||||||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | |||||||
Recruitment Information | |||||||
Recruitment Status ICMJE | Recruiting | ||||||
Estimated Enrollment ICMJE | 620 | ||||||
Original Estimated Enrollment ICMJE | 147 | ||||||
Estimated Study Completion Date ICMJE | February 3, 2024 | ||||||
Estimated Primary Completion Date | February 3, 2024 (Final data collection date for primary outcome measure) | ||||||
Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
| ||||||
Sex/Gender ICMJE |
| ||||||
Ages ICMJE | 18 Years and older (Adult, Older Adult) | ||||||
Accepts Healthy Volunteers ICMJE | No | ||||||
Contacts ICMJE |
| ||||||
Listed Location Countries ICMJE | Australia, Canada, France, Japan, Poland, Taiwan, United Kingdom, United States | ||||||
Removed Location Countries | Netherlands | ||||||
Administrative Information | |||||||
NCT Number ICMJE | NCT02554812 | ||||||
Other Study ID Numbers ICMJE | B9991004 2015-002552-27 ( EudraCT Number ) JAVELIN MEDLEY ( Other Identifier: Alias Study Number ) | ||||||
Has Data Monitoring Committee | No | ||||||
U.S. FDA-regulated Product | Not Provided | ||||||
IPD Sharing Statement ICMJE |
| ||||||
Responsible Party | Pfizer | ||||||
Study Sponsor ICMJE | Pfizer | ||||||
Collaborators ICMJE | Not Provided | ||||||
Investigators ICMJE |
| ||||||
PRS Account | Pfizer | ||||||
Verification Date | January 2021 | ||||||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |